BMS拿下CAR-T明星公司!诺华、强生/传奇、吉利德等如何接招?

医药经济报
14 Mar

百时美施贵宝(BMS)再次吹响进军号角,CAR-T市场风云又起。当地时间3月11日,BMS以总股权价值2.86亿美元收购2seventy公司,将双方联合开发的BCMA CAR-T细胞疗法(Abecma)完全纳入旗下。Abecma是BMS第二款CAR-T细胞产品。此次收购,彰显了BMS在CAR-T疗法领域的决心,也代表2seventy的完美谢幕。随着各大跨国药企2024年财报的出炉,CAR-T疗法...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10